Perfil de la empresa · Healthcare

10X Genomics Inc

TXG · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
12 de septiembre de 2019
Empleados
1178
Precio actual
$34.76
En vivo · 18 de junio de 2026
Compra razonable
≤ $16
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
42/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $34.76 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $14–$16 / razonable $28–$38 / optimista $54–$60. A $34.76, Dentro del rango de valor intrínseco razonable.

Al publicar $28.84 (15 de junio de 2026)

Aún no hay análisis sobre este valor en tu idioma.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Capitalización4079,1 MUS$
Ingresos (TTM)638,78 MUS$
EBITDA-30,67 MUS$
Margen neto-3,55 %
ROE-2,98 %
PER previsto526,32
BPA-0,17 US$
Rango de 52 semanas10,48 US$ – 35,65 US$
Precio objetivo de analistas25,77 US$
Recomendación de analistas3.8 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.